Center for Drug Safety & Effectiveness
Drawing on the combined expertise of the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins School of Medicine, the Center for Drug Safety and Effectiveness serves as a nexus for individuals at Johns Hopkins who are involved in research, education, clinical programs and public service to improve prescription drug use and pharmaceutical policy in the United States and around the world. The unparalleled knowledge base of the Center’s core faculty reflects a diversity of fields, ranging from pharmacovigilance to regulatory policy.
- COVID-19 Outcomes for Patients on Immunosuppressive Drugs on Par with Non- Immunosuppressed Patients
Newswise, January 7, 2021
- Hospitals Forced To Be More Transparent About Pricing. Will That Save You Money?
NPR, January 5, 2021
- Amid Pandemic, Scientists Reassess Routine Medical Care
New York Times, December 12, 2020
- Trump boasted he made insulin so cheap ‘it’s like water.’ Americans with diabetes beg to differ.
Washington Post, October 1, 2020
- FDA approved opioids based on limited data, sometimes ‘flawed’ trial designs
Healio.com, September 28, 2020
- Debate rages over whether FDA should use emergency powers to clear coronavirus vaccine early
Washington Post, September 3, 2020
- Popular blood pressure medicines do not put patients at greater COVID-19 risk, new study finds
Reuters, June 12, 2020
- Trump officials, health experts worry coronavirus will set back opioid fight
Politico, April 10, 2020
Jodi Segal, MD, MPH, Center Co-Director, was recently elected to be a Fellow of the International Society of Pharmacoepidemiology (a FISPE) in recognition of her contributions to the field and to the Society.Learn More
New Course Offering
Study Design and Analysis for Causal Inference With Time-Varying Exposures (340.776.01) is being offered during the 4th Term (Course Instructor: John W. Jackson).Learn More